5 companies in Kurma Partners's investment portfolio.
Back to Kurma Partners profile“Invests in early-stage life sciences companies developing innovative therapeutics, medical devices, and diagnostic technologies.”
Carmat develops artificial heart devices designed to replace the function of a failing heart in patients with end-stage heart failure.
Company with limited publicly available information about its business operations and sector focus.
Biotechnology company developing enzymatic DNA synthesis technology to enable on-demand, decentralized production of synthetic DNA for research and therapeutics.
French biopharmaceutical company developing therapeutic and diagnostic solutions for metabolic and liver diseases, including NASH.
Biotech company developing scalable cell therapy manufacturing technologies using innovative 3D cell culture and microcarrier systems.
Kurma Partners has built a portfolio of 5 companies across 1 sector, including Biotech.
The portfolio reflects investments across the IPO, Series B stages, showing Kurma Partners's approach to supporting companies at multiple points in their growth journey.
Kurma Partners has invested in 5+ companies across 1 different sectors.
Kurma Partners's portfolio spans Biotech. This diversification reflects the firm's broad investment thesis and sector expertise.
Kurma Partners invests across the IPO, Series B stages. Their portfolio includes companies at various points in their growth journey.